Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Pharmacy · Oncology, Hematology, PharmacyMedium impact

08.02.38a, Zenocutuzumab-zbco (Bizengri®)

Act
by Jun 1, 2026
Effective date
Jun 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross expanded coverage for Zenocutuzumab-zbco (Bizengri®) by removing a parenthetical exclusion from non-small cell lung cancer criteria and adding 18 new ICD-10 diagnosis codes for pancreatic and lung malignancies effective June 1, 2026. Billing teams must update systems to recognize these newly covered diagnosis codes for claim submission.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jun 1, 2026 · 4 steps
01Billing team must update claim submission system to recognize the 18 newly added ICD-10 diagnosis codes (C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, C25.9, C33, C34.01, C34.02, C34.11, C34.12, C34.2, C34.31, C34.32, C34.81, C34.82, C34.91, C34.92) as covered indications when paired with HCPCS code J9382.
02Oncology providers and billing staff must verify that patient claims for Bizengri® include medical necessity documentation showing: NRG1 gene fusion-positive disease, disease progression on or after prior systemic therapy, LVEF ≥50%, and appropriate ECOG performance status (0-2) for pancreatic adenocarcinoma cases.
03Remove any hard stops or denial rules that previously applied to the deleted NSCLC parenthetical exclusion.
04Claims submitted before June 1, 2026 with these codes will be denied if system rules are not updated.

Codes mentioned

J9382C25.0C25.1C25.2C25.3C25.7C25.8C25.9C33C34.01C34.02C34.11C34.12C34.2C34.31C34.32C34.81C34.82C34.91C34.92

Original notice

08.02.38a, Zenocutuzumab-zbco (Bizengri®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.183a, Zenocutuzumab-zbco (Bizengri®)MediumEffective Jun 1, 2026 · PharmacyMA08.185a, Datopotamab deruxtecan (Datroway®)MediumEffective Nov 2, 2026 · Pharmacy08.02.41a, Datopotamab deruxtecan (Datroway®)MediumEffective Nov 2, 2026 · PharmacyMA08.183, Zenocutuzumab-zbco (Bizengri®)MediumEffective Jul 28, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyHematologyPharmacyCode J9382Code C25.0Code C25.1Code C25.2Code C25.3Code C25.7Code C25.8Code C25.9Code C33Code C34.01Code C34.02Code C34.11Code C34.12Code C34.2Code C34.31Code C34.32Code C34.81Code C34.82Code C34.91Code C34.92

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account